Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its lead product candidate is taletrectinib, an ROS1 inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer; Safusidenib, a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; NUV-868, a binding domain 2 selective, oral, small molecule bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4. The company was founded in 2018 and is headquartered in New York, New York.

Nuvation Bio Inc. Class A

TD Cowen analyst Yaron Werber reiterated a Buy rating on Nuvation Bio on November 18. The company’s shares closed yesterday at $4.80. According to ...

Nuvation Bio (NUVB) Receives a Buy from TD Cowen

Nuvation Bio ( ($NUVB) ) has provided an update. On November 8, 2025, Nuvation Bio announced positive results from a Phase 2 study of safusidenib i...

Nuvation Bio Reports Positive Phase 2 Study Results

In a report released yesterday, Yaron Werber from TD Cowen reiterated a Buy rating on Nuvation Bio. The company’s shares closed yesterday at $5.17....

Current Quarter	$-0.11	Next Quarter	$-0.13
Current Year	$-0.6	Next Year	$-0.49
QoQ Growth	-18.2%	YoY Growth	+18.3%
3Y EPS CAGR	-68.6%	Target Price	$8.83
Consensus	Buy	Upside	+26.3%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NUVB	$6.99	-0.29%	11.22M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NUVB	$6.99	-0.3%	11.22M
3
4
5
6

NUVB

NUVB

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Nuvation Bio Inc. Class A Data in Excel

Get Nuvation Bio Inc. Class A Data in Excel